Previous close | 23.30 |
Open | 23.30 |
Bid | 24.55 |
Ask | 29.00 |
Strike | 67.50 |
Expiry date | 2026-01-16 |
Day's range | 23.30 - 23.30 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.